Cardiovascular Drugs Market to Witness an Outstanding Growth by 2025

According to the research report, the global cardiovascular drugs market was valued at US$ 142.56 bn in 2016. Between the forecast period of 2017 and 2025, the global market is expected to register a CAGR of 1.5% to reach a valuation of US$162.96 bn by the end of 2025. Out of the various distribution channels in the global market, the retail pharmacies segment is estimated to soar ahead of others. This segment is projected to exhibit a CAGR of 1.5% between 2017 and 2025. Geographically, North America is projected to stay ahead of others in the overall market in the forecast period.

Transparency Market Research (TMR) states that the global cardiovascular drugs market is poised to witness introduction several novel drugs in the coming years. Leading players such as AstraZeneca, Pfizer, and Novartis are expected to make bold moves during the forecast period of 2017 and 2025. Increasing investments in research and development and growing number of medical trials are expected to have to intensify the competition in the global market. Mergers and acquisitions are also anticipated to be a key strategy of the players to show their dominance in the global market. For instance, AstraZeneca and Recordati have agreed to work together to gain commercial rights to retail Seloken along with related Logimax fixed-dose combination treatments all across Europe.

Read Report Overview @ https://www.transparencymarketresearch.com/cardiovascular-drugs-market.html

Statistics presented by America Heart Foundation state that the number of people suffering from CVD are likely to reach 23.6 mn by the end of 2030. The alarming rise in the number is expected to increase the sale of cardiovascular drugs in the near future. Analysts predict that majority of the CVD patients have to be administered medicines for a long-term basis, which requires close monitoring. Growing number of drugs in the pipeline, improving approval rates, and better awareness about CVDs, especially in developing economies, has also had a major impact on the overall market. The surge in geriatric population and soaring number of diabetics around the world have also been identified as the key factors that will be responsible for the rise of this global market.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33281

Patent Expiries to Challenge Cardiovascular Drugs Market Growth

Despite the strong market drivers, the global cardiovascular drugs market faces some tough restraints. Currently, patent expiries is likely to hamper market’s growth. This will not only open up the market for generics but also bring down prices as competition intensifies. Furthermore, the poor rate of healthcare sector’s growth in the developing economies of Asia Pacific is anticipated to challenge the global market.

Request Cardiovascular Drugs Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33281

This review is based on Transparency Market Research’s report, titled “Cardiovascular Drugs Market (Drug Class – Anti hyperlipidemics, Anti-hypertensives, Anti-coagulants, Anti-fibrinolytics, and Anti-arrhythmic; Distribution Channels – Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”.

Buy Full Cardiovascular Drugs Market Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=33281<ype=S

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/

This release was published on openPR.